The latest progress report on NMN in human trials

On December 19, 2019, Keio University in Japan released the latest progress in human clinical trials of NMN.

The authors conducted a clinical trial to investigate the safety of a single dose of NMN in 10 healthy men. Single-arm non-random interventions were administered in a single oral dose of 100, 250, and 500 mg of NMN. Clinical findings and parameters as well as pharmacokinetics of NMN metabolites were studied 5 h after each intervention.

Conclusion:

1. Single oral administration of NMN did not cause any obvious clinical symptoms or changes in heart rate, blood pressure, oxygen saturation or body temperature, and laboratory analysis results showed no significant changes.

2. In healthy men, a single oral dose of 500mg-NMN is safe and effective without causing any obvious harmful effects. Thus, oral NMN is found to be feasible and may be a therapeutic strategy to supplement cellular NAD + levels to alleviate age-related dysfunction in humans.

3. Since no adverse events such as nausea were observed, NMN in this study did not increase the blood level of nicotinamide or cause any adverse events. In addition, high doses of nicotinamide have been reported to cause hepatotoxicity, but we did not observe any adverse effects of NMN on liver enzymes.

4. Plasma bilirubin levels increased while glucose levels decreased significantly. These changes are most likely due to a five-hour fast.

Paper:

https://doi.org/10.1507/endocrj.EJ19-0313

Data source:

https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ19-0313/_article